BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
Europe - FRA:BSX - US1011371077 - Common Stock
84.8 EUR
+0.4 (+0.47%)
We assign a fundamental rating of 5 out of 10 to BSX. BSX was compared to 59 industry peers in the Health Care Equipment & Supplies industry. BSX has only an average score on both its financial health and profitability. BSX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
BSX had positive earnings in the past year.
BSX had a positive operating cash flow in the past year.
BSX had positive earnings in 4 of the past 5 years.
In the past 5 years BSX always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of BSX (6.03%) is better than 67.80% of its industry peers.
BSX has a better Return On Equity (11.17%) than 67.80% of its industry peers.
BSX has a better Return On Invested Capital (7.66%) than 66.10% of its industry peers.
BSX had an Average Return On Invested Capital over the past 3 years of 6.54%. This is below the industry average of 9.04%.
The 3 year average ROIC (6.54%) for BSX is below the current ROIC(7.66%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROIC | 7.66% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
The Profit Margin of BSX (13.54%) is better than 77.97% of its industry peers.
BSX's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 18.69%, BSX is in the better half of the industry, outperforming 79.66% of the companies in the same industry.
BSX's Operating Margin has been stable in the last couple of years.
BSX has a better Gross Margin (68.30%) than 76.27% of its industry peers.
BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BSX is destroying value.
BSX has more shares outstanding than it did 1 year ago.
BSX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BSX has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.52 indicates that BSX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.52, BSX belongs to the top of the industry, outperforming 86.44% of the companies in the same industry.
The Debt to FCF ratio of BSX is 3.33, which is a good value as it means it would take BSX, 3.33 years of fcf income to pay off all of its debts.
BSX has a Debt to FCF ratio of 3.33. This is in the better half of the industry: BSX outperforms 74.58% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that BSX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.50, BSX perfoms like the industry average, outperforming 40.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Altman-Z | 5.52 |
ROIC/WACC0.94
WACC8.17%
2.3 Liquidity
A Current Ratio of 1.37 indicates that BSX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.37, BSX perfoms like the industry average, outperforming 45.76% of the companies in the same industry.
BSX has a Quick Ratio of 1.37. This is a bad value and indicates that BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
BSX has a worse Quick ratio (0.82) than 62.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.91% over the past year.
The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
Looking at the last year, BSX shows a very strong growth in Revenue. The Revenue has grown by 21.45%.
BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.30% yearly.
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
3.2 Future
BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.40% yearly.
Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 12.12% on average per year.
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 35.04, which means the current valuation is very expensive for BSX.
The rest of the industry has a similar Price/Earnings ratio as BSX.
The average S&P500 Price/Earnings ratio is at 27.69. BSX is valued slightly more expensive when compared to this.
The Price/Forward Earnings ratio is 28.86, which means the current valuation is very expensive for BSX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BSX is on the same level as its industry peers.
BSX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.18.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.04 | ||
| Fwd PE | 28.86 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit more expensive than 64.41% of the companies in the same industry.
62.71% of the companies in the same industry are more expensive than BSX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.13 | ||
| EV/EBITDA | 33.07 |
4.3 Compensation for Growth
BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
BSX's earnings are expected to grow with 15.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.75
PEG (5Y)3.67
EPS Next 2Y16.93%
EPS Next 3Y15.51%
5. Dividend
5.1 Amount
No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BSX (10/17/2025, 7:00:00 PM)
84.8
+0.4 (+0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.27%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap125.65B
Analysts86.34
Price Target108.53 (27.98%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)2.16%
PT rev (3m)3.02%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)2.33%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.17%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)2.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.04 | ||
| Fwd PE | 28.86 | ||
| P/S | 7.94 | ||
| P/FCF | 42.13 | ||
| P/OCF | 34.26 | ||
| P/B | 6.55 | ||
| P/tB | N/A | ||
| EV/EBITDA | 33.07 |
EPS(TTM)2.42
EY2.85%
EPS(NY)2.94
Fwd EY3.46%
FCF(TTM)2.01
FCFY2.37%
OCF(TTM)2.48
OCFY2.92%
SpS10.69
BVpS12.95
TBVpS-1.69
PEG (NY)1.75
PEG (5Y)3.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROCE | 9.51% | ||
| ROIC | 7.66% | ||
| ROICexc | 7.77% | ||
| ROICexgc | 26.52% | ||
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% | ||
| FCFM | 18.84% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexcg growth 3Y8.56%
ROICexcg growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 60.84% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 89.77% | ||
| Profit Quality | 139.08% | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 5.52 |
F-Score5
WACC8.17%
ROIC/WACC0.94
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.06%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%